Safety study of nesiritide (human b-type natriuretic peptide) for the treatment of hospitalized patients with acutely decompensated CHF
Uri Elkayam(Icahn School of Medicine at Mount Sinai), Darlene P. Horton(Scion), W. Herbert Haught, Matthew Neibaur(Jacksonville University)
Cited by 4
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
|European Journal of Heart Failure|2010|1.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies
|New England Journal of Medicine|2016|597